Use of 4% tetrasodium EDTA (KiteLock™) to prevent central venous catheter–related bloodstream infections in pediatric hemodialysis patients
Pediatric Nephrology · 2025
DOI: 10.1007/s00467-024-06601-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von Cal H Robinson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. cal.robinson@sickkids.ca. Hauptthemen laut MEDLINE: Renal Dialysis, Catheter-Related Infections, Edetic Acid, Central Venous Catheters. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Central venous catheter (CVC)-related bloodstream infections (CRBSI) are common in children receiving hemodialysis and cause significant morbidity and healthcare costs. Unlike standard locking solutions, 4% tetrasodium EDTA (KiteLock™) has antimicrobial and antibiofilm properties. We aimed to study the safety and efficacy of 4% tetrasodium EDTA CVC locking in pediatric hemodialysis. METHODS: Single-center, before-and-after quality improvement study. We included all chronic hemodialysis patients (6 months-18 years) from 2016-2022 (before) to 2022-2024 (after). The standard CVC locking solution was changed from heparin (1000 units/mL) to 4% tetrasodium EDTA. We compared unit-level incidence of CRBSI, CVC replacement procedures (exchange or removal and reinsertion), laboratory results, alteplase use, and adverse events before and after 4% tetrasodium EDTA implementation. RESULTS: We included 22 pediatric chronic hemodialysis patients (median age 13.5 years, 50% female). CRBSI incidence was 0.89 infections per 1000 catheter-days (25,769 total catheter-days) before and 0.18 per 1000 catheter-days (5426 total catheter-days) after 4% tetrasodium EDTA (IRR 0.21, 95%CI 0.03-1.52). CVC replacement procedure incidence was 1.99 procedures per 1000 catheter-days (4027 total catheter-days) before and 1.29 per 1000 catheter-days (5426 total catheter-days) after 4% tetrasodium EDTA (IRR 0.65, 95%CI 0.24-1.79). There were no significant differences in hemodialysis treatment parameters, alteplase use (12% of treatments before vs. 18% after), or access complications (12% of treatments before vs. 15% after). CONCLUSIONS: CVC locking with 4% tetrasodium EDTA was associated with sustained reductions in CRBSI and CVC replacement procedure incidence. Incorporation of 4% tetrasodium EDTA locking into standardized CVC care bundles may prolong vascular access survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. cal.robinson@sickkids.ca.
- Department of Paediatrics, The University of Toronto, Toronto, Ontario, Canada. cal.robinson@sickkids.ca.
- Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada. cal.robinson@sickkids.ca.
- Peter Gilgan Centre for Research and Learning, SickKids Research Institute, 686 Bay St, Toronto, Ontario, M5G 0A4, Canada. cal.robinson@sickkids.ca.
- Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Paediatrics, The University of Toronto, Toronto, Ontario, Canada.
Zitieren
APA
Robinson, C. H., Harvey, E., Nemec, R., Karkut, K., Tecson, L., & McKay, A. M. (2025). Use of 4% tetrasodium EDTA (KiteLock™) to prevent central venous catheter–related bloodstream infections in pediatric hemodialysis patients. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06601-4
Vancouver
Robinson CH, Harvey E, Nemec R, Karkut K, Tecson L, McKay AM. Use of 4% tetrasodium EDTA (KiteLock™) to prevent central venous catheter–related bloodstream infections in pediatric hemodialysis patients. Pediatric Nephrology. 2025. doi:10.1007/s00467-024-06601-4
BibTeX
@article{Robinson2025,
author = {Robinson, Cal H and Harvey, Elizabeth and Nemec, Rose and Karkut, Katherine and Tecson, Lor and McKay, Ashlene M},
title = {Use of 4% tetrasodium EDTA (KiteLock™) to prevent central venous catheter–related bloodstream infections in pediatric hemodialysis patients},
journal = {Pediatric Nephrology},
year = {2025},
doi = {10.1007/s00467-024-06601-4}
}
EUVIMED